AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vanda Pharmaceuticals Inc. Director's Dealing 2022

Aug 1, 2022

33390_dirs_2022-08-01_18755c55-7b3f-4276-a996-80fc71e846ca.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2022-07-28

Reporting Person: Moran Kevin Patrick (SVP, CFO & Treasurer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-07-28	Common Stock	S	2239	$10.97	Disposed	117452	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	635	Indirect

Footnotes

F1: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.